biomedicine

At the HIV Vaccine World Congress, which is taking place in Barcelona between the 7^th and 10^th October, Catalan researchers presented a vaccine prototype that has proven to be effective in clinical studies conducted with mice and monkeys. The vaccine stimulates the creation of antibodies and attacks infected cells. The prototype has been created by the Catalan programme to develop a vaccine against HIV, HIVACAT. According to the programme’s Scientific Director, Christian Brander, the vaccine could eventually also be used as a therapeutic treatment.

According to a medical study developed in Barcelona’s Hospital Clínic, fetuses conceived by assisted reproduction have changes in their heart and arteries, which begin even before birth and persist in the postnatal period. These changes represent a significant increase in cardiovascular risk in adulthood. However, the researchers point out that this situation is reversible from the beginning of life through a diet rich in omega3 and other factors. In addition, they strongly emphasised that this is only a risk factor and not a disease. The study leader, Eduard Gratacós, said that “it's a message of opportunity, not alarm”. Furthermore, they also recommend monitoring the blood pressure of these babies.

Christian Brander is a researcher at the IrsiCaixa AIDS Research Institute and Scientific Director of HIVACAT, the programme for the development of a HIV vaccine. He graduated from the University of Bern in 1994 with a PhD in Immunology and has spent 13 years at Harvard University focusing on cellular immunity to viral infections.

The Catalan research centre has unveiled a new 625-square-metre space where the Academic Research Organisation (ARO) will be based. The ARO will provide support for clinical trials developed throughout the world regarding quality control, methodological, regulatory, statistical and management aspects. Furthermore, the new space has 7 medical boxes, nursery support and a lab to process the samples, which will provide an integral service for clinical trials. The new facilities will be able to host between 750 and 1,100 patients per year and work on 350 trials. It cost €1.2 million, which came from public funds.

50% of tumours are related to mutations of this gene, according to the researchers. A study developed by the Bellvitge Institute of Biomedical Research (IBIDELL), based in Greater Barcelona, and the University of Cincinnati have discovered the role of the noncoding 5S rRNA molecule. This molecule regulates the P53 Tumour Suppressor Gene, which protects healthy cells from turning into cancerous cells. When the cell functions correctly, the levels of P53 are low and stable, but when something wrong is detected, the levels increase and cause the cell’s death, avoiding the development of a tumour. The director of the study, George Thomas, explained that understanding how the P53 works and regulates itself is extremely important since “more than half of the tumours present mutations of this gene”.

The exposure to music during in vitro fertilisation has a positive impact on the fecundity rate of egg cells according to a study developed by the assisted reproduction centre Institut Marquès, based in Barcelona. The study concludes that the micro vibrations in the music shake the culture liquid in which the ovum swims and this improves the distribution of nutrients and also avoids the accumulation of toxic products. As a result, the fertilisation of the ovum is facilitated and the success rate is improved by 4.8%. Three styles of music were tested (pop, heavy metal and classical) but no significant differences were observed in relation to the different frequencies.

Mateu Hernández is the General Director of Barcelona Global, an independent private association that is trying to make Barcelona one of the best cities in the world to attract talent and business activity. Its activities are similar to associations like Partnership for New York, Berlín & Partners and London & Partners, for example. Barcelona Global is made up of the main research centres in the city, prestigious professionals from the Catalan capital or related to it, and more than thirty of the most powerful and innovative companies in Barcelona.

The vaccine works by re-introducing immune system cells, which have previously been extracted and modified, in order to avoid the destruction of beta cells, which are those producing insulin. The vaccine has been developed by researchers from the Germans Trias Hospital in Badalona, in Greater Barcelona. Furthermore, in February, another group of Catalan scientists announced the cure of Type 1 Diabetes in two dogs, which is the first time this has been successful in large animals. In the last few years, Catalonia and especially Greater Barcelona have become a world centre within the biomedicine sector.

Between the 11th and 13th of March, Barcelona will host the spring meeting of Bio-Europe, the continent’s largest partnering conference of the global biotechnology industry, for the second time. 1,300 biomedical companies will participate in the event, with more than 2,000 delegates and executives. 60 out of the 100 Spanish companies attending are from Catalonia. In the last decade, Catalonia, particularly the Greater Barcelona area, has become the most important centre in Southern Europe within the biomedical field and one of the main centres internationally. Barcelona’s Deputy Mayor for Economic Affairs, Sònia Recasens, praised the importance of the event as it boosts those “added-value sectors that are strategic for the city’s economic growth”.

The company, which is based in Greater Barcelona, is the world’s third leader in blood derivatives pharmaceutical products. Last year, it bought out its main competitor in the United States, Talecris. Grífols had a €2.62 billion turnover in 2012 and almost doubled its sales compared to the 2011 figures. The company’s net profit last year quadruples that of 2011. The good results are due to a significant reduction in debt levels and Grífols’ penetration into the United States market. Besides, this week it announced it bought for €37 million the 60% of Progenika Biopharma’s capital, a Basque biotechnology company specialised in the design of diagnostic tests.

The Catalan Institute of Oncology (ICO) has introduced a world pioneering technique which allows four out of five patients who cannot undergo surgery to survive the illness. This technique causes less after-effects than the traditional radiotherapy. Furthermore, statistics show that with the regular treatment, two thirds of these patients die. However, Ferran Gadea, the Head of the Radiotherapy and Oncology Service, says that the best option to cure a lung cancer is still to undergo the operation when possible.

This is a real stride for the cancer research. The effects of a protein called condensing on colorectal cancer have been found out by a team of Molecular Biology and Biochemistry experts, at the Research Centre for Nanomedicine (CIBBIN-Nanomedicine) at the Vall d'Hebon Research Institute. The researchers have discovered that condensin helps the tumor cells to divide rapidly, so its inhibition leads to the death of tumour cells. The results of this research were published in the 'Journal of Biology and Chemistry', and they constitute a real hope for the fight against colorectal cancer.

The technique started in Catalonia in 2007 and by 2011 it was practiced on 40% of patients with renal failure. The Catalan Health Ministry hopes to cover 100% of the cases within the next 5 to 10 years. In the United States it started being used a year ago as they were waiting for clinical results to expand its use. Now, a clinical study on 900 patients from 27 different Catalan centres has proved that the technique reduces mortality by 30% on patients with kidney failure within the first three years. In addition, it improves quality of life, reduces hospitalisations by 22% and it also makes hypotension episodes drop by 28%.

Researchers from the Universitat Autònoma de Barcelona (UAB) have managed to completely cure dogs with type 1 diabetes through a single session of gene therapy. It is the first time ever that the effectiveness of a treatment against this illness in large animals has been proved in the world. This achievement opens the door to being able to translate a similar therapy to humans and cure type 1 diabetes, which currently has no cure and means that patients have to control their blood insulin levels for their whole lives through hormone injections, as untreated it can be fatal. Diabetes mellitus type 1 is an autoimmune illness that destroys the cells of the pancreas that produce insulin, an essential hormone in the process of transforming glucose into energy for the body’s cells.

Through its FET-Flagship programme, the European Commission is allocating €1 billion to each of the two main research projects in Europe. The first one is a project to explore the properties of graphene, a new material deriving from graphite that might revolutionise industry as silicon did a few decades ago. The second one will simulate a human brain in order to understand how it exactly works. The Catalan Institute of Nanotechnology is one of the nine leading institutes coordinating the graphene project, in which 623 research groups from 32 different countries will participate. Furthermore, the Barcelona Supercomputing Center will take care of the calculations at a molecular level in the Human Brain Project.